Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT1 | P31749 | 20/20 | 0.73 |
| ▸ | CDK2 | P24941 | 11/20 | 0.73 |
| ▸ | SGK1 | O00141 | 1/20 | 0.57 |
| ▸ | CDK1 | P06493 | 1/20 | 0.43 |
| ▸ | KIT | P10721 | 1/20 | 0.43 |
| ▸ | KDR | P35968 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4296759 | 1.00 | AKT1 (0.73) | AKT1CDK2SGK1CDK1KIT | |
| SCHEMBL4296768 | 1.00 | AKT1 (0.73) | AKT1CDK2SGK1CDK1KIT | |
| SCHEMBL4297950 | 0.92 | AKT1 (0.73) | AKT1CDK2SGK1CDK1KIT | |
| SCHEMBL4297953 | 0.92 | AKT1 (0.73) | AKT1CDK2SGK1CDK1KIT | |
| SCHEMBL4297951 | 0.92 | AKT1 (0.73) | AKT1CDK2SGK1CDK1KIT | |
| SCHEMBL4301368 | 0.88 | AKT1 (0.76) | AKT1CDK2SGK1 | |
| SCHEMBL4301374 | 0.88 | AKT1 (0.76) | AKT1CDK2SGK1 | |
| SCHEMBL4301371 | 0.88 | AKT1 (0.76) | AKT1CDK2SGK1 | |
| SCHEMBL4294180 | 0.88 | AKT1 (0.69) | AKT1CDK2SGK1 | |
| SCHEMBL4294186 | 0.88 | AKT1 (0.69) | AKT1CDK2SGK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1981884-B1 | THIAZOLE COMPOUNDS AS PROTEIN KINASE B (PKB) INHIBITORS | AMGEN INC (US) | 2012-06-13 | — | — | EP | disclosed |
| US-8084479-B2 | Thiazole compounds and methods of use | AMGEN INC. (US) | 2011-12-27 | — | — | US | disclosed |
| US-20090270445-A1 | Thiazole compounds and methods of use | AMGEN INC. (US) | 2009-10-29 | — | — | US | disclosed |
| US-7514566-B2 | Thiazole compounds and methods of use | AMGEN, INC. (US) | 2009-04-07 | — | — | US | disclosed |
| US-20070173506-A1 | Thiazole compounds and methods of use | AMGEN INC. (US) | 2007-07-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090270445-A1 | Thiazole compounds and methods of use | MTOR, JAK2, TK2 | AKT1 80/4885CDK2 11/4885SGK1 98/4885 |
| US-20070173506-A1 | Thiazole compounds and methods of use | MTOR, JAK2, PCK2 | AKT1 143/4885CDK2 62/4885SGK1 163/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.